Bicyclol Regulates Hepatic Gluconeogenesis in Rats with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease by Inhibiting Inflammation

Hepatic gluconeogenesis plays an important role in maintaining the body's glucose metabolism homeostasis. Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver diseases, when combined with type 2 diabetes mellitus (T2DM), it can cause severe glucose metabolism disorders. Studies have confirmed that chronic liver inflammatory lesions are the basis of T2DM combined with NAFLD (T2DM-NAFLD), inhibiting liver inflammation can improve glucose metabolism disorders. It is essential to explore safe and effective drugs to inhibit liver inflammation to improve the body's glucose metabolism disorders. Bicyclol is a biphenyl derivative that has anti-oxidative and anti-inflammatory properties. In the present study, the hepatoprotective effects and underlying mechanisms of bicyclol in T2DM-NAFLD were investigated, and T2DM-NAFLD with/without bicyclol treatment models were established. The results revealed that bicyclol alleviated fasting blood glucose, serum transaminase levels, insulin resistance, hepatic adipogenesis, lipid accumulation and markedly reduced T2DM-NAFLD rat histological alterations of livers. Not only that, bicyclol markedly attenuated T2DM-NAFLD induced production of inflammation factors (IL-1 beta and TNF-alpha). Moreover, bicyclol suppressed the expression of insulin/gluconeogenesis signaling pathway (Akt, PGC-1 alpha and PEPCK). These findings suggested that bicyclol might be a potentially effective drug for the treatment of T2DM-NAFLD and other metabolic disorders.

Automated summary

Hepatic gluconeogenesis is crucial in maintaining glucose metabolism homeostasis, particularly in cases of type 2 diabetes mellitus combined with non-alcoholic fatty liver disease (T2DM-NAFLD). Inhibiting liver inflammation has been shown to improve glucose metabolism disorders. Studies suggest that Bicyclol may be an effective drug for treating T2DM-NAFLD and other metabolic disorders.